Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

Stuart Emanuel, Robert H. Gruninger, Angel Fuentes-Pesquera, Peter J. Connolly, Jennifer A. Seamon, Susan Hazel, Rose Tominovich, Beth Hollister, Cheryl Napier, Michael R. D'Andrea, Michael Reuman, Gilles Bignan, Robert Tuman, Dana Johnson, David Moffatt, Mark Batchelor, Anne Foley, James O'Connell, Rodger Allen, Martin Perry, Linda Jolliffe and Steven A. Middleton
Molecular Pharmacology September 2004, 66 (3) 635-647; DOI: https://doi.org/10.1124/mol.104.000638
Stuart Emanuel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert H. Gruninger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angel Fuentes-Pesquera
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Connolly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Seamon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Hazel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rose Tominovich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beth Hollister
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Napier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. D'Andrea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Reuman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Bignan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Tuman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Moffatt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Batchelor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Foley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James O'Connell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodger Allen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Perry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Jolliffe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Middleton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Inhibition of angiogenesis may have wide use in the treatment of cancer; however, this approach alone will not cause tumor regression but may only slow the growth of solid tumors. The clinical potential of antiangiogenic agents may be increased by combining them with conventional chemotherapeutics. 4-[4-(1-Amino-1-methylethyl)phenyl]-2-[4-(2-morpholin-4-yl-ethyl)phenylamino]pyrimidine-5-carbonitrile (JNJ-17029259) represents a novel structural class of 5-cyanopyrimidines that are orally available, selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2) and other tyrosine kinases involved in angiogenesis, such as platelet-derived growth factor receptor, fibroblast growth factor receptor, VEGF-R1, and VEGF-R3, but have little activity on other kinase families. At nanomolar levels, JNJ-17029259 blocks VEGF-stimulated mitogen-activated protein kinase signaling, proliferation/migration, and VEGF-R2 phosphorylation in human endothelial cells; inhibits the formation of vascular sprouting in the rat aortic ring model of angiogenesis; and interferes with the development of new veins and arteries in the chorioallantoic membrane assay. At higher concentrations of 1 to 3 μM, this compound shows antiproliferative activity on cells that may contribute to its antitumor effects. JNJ-17029259 delays the growth of a wide range of human tumor xenografts in nude mice when administered orally as single-agent therapy. Histological examination revealed that the tumors have evidence of reduced vascularity after treatment. In addition, JNJ-17029259 enhances the effects of the conventional chemotherapeutic drugs doxorubicin and paclitaxel in xenograft models when administered orally in combination therapy. An orally available angiogenesis inhibitor that can be used in conjunction with standard chemotherapeutic agents to augment their activity may have therapeutic benefit in stopping the progression of cancer and preventing metastasis.

  • Received March 19, 2004.
  • Accepted June 9, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 66 (3)
Molecular Pharmacology
Vol. 66, Issue 3
1 Sep 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

Stuart Emanuel, Robert H. Gruninger, Angel Fuentes-Pesquera, Peter J. Connolly, Jennifer A. Seamon, Susan Hazel, Rose Tominovich, Beth Hollister, Cheryl Napier, Michael R. D'Andrea, Michael Reuman, Gilles Bignan, Robert Tuman, Dana Johnson, David Moffatt, Mark Batchelor, Anne Foley, James O'Connell, Rodger Allen, Martin Perry, Linda Jolliffe and Steven A. Middleton
Molecular Pharmacology September 1, 2004, 66 (3) 635-647; DOI: https://doi.org/10.1124/mol.104.000638

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

Stuart Emanuel, Robert H. Gruninger, Angel Fuentes-Pesquera, Peter J. Connolly, Jennifer A. Seamon, Susan Hazel, Rose Tominovich, Beth Hollister, Cheryl Napier, Michael R. D'Andrea, Michael Reuman, Gilles Bignan, Robert Tuman, Dana Johnson, David Moffatt, Mark Batchelor, Anne Foley, James O'Connell, Rodger Allen, Martin Perry, Linda Jolliffe and Steven A. Middleton
Molecular Pharmacology September 1, 2004, 66 (3) 635-647; DOI: https://doi.org/10.1124/mol.104.000638
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Nelfinavir and PXR
  • P2X7 Positive Modulator Structure-Activity Relationship
  • Predicting Drug Interactions with ENT1 and ENT2
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics